Process for preparation of improved mutant strain of Bordetella bronchiseptica useful for live attenuated vaccine for protection of B. bronchiseptica infection and live attenuated AR vaccine produced therefrom
US4770875A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Nov 10, 1987 |
| Grant date | Sep 13, 1988 |
| Priority date | — |
| Expiry date | Nov 10, 2007 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S424/83
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A process for the preparation of a mutant strain of B. bronchiseptica having chromosomal genetic markers carrying at least temperature-sensitive (grown at 42.degree. C.), nalidixic acid-resistant and heat-labile dermonecrotic toxin producing ability negative markers, suitable for the preparation of live attenuated AR vaccine, which comprises subjecting a strain of B. bronchiseptica to an induced mutation, isolating a mutant having the genetic markers of being at least temperature-sensitive (grown at 42.degree. C.), nalidixic acid-resistant and heat-labile dermonecrotic toxin negative, culturing the isolated strain of B. bronchiseptica on a Bordet-gengou agar plate containing nalidixic acid at 42.degree. C., thereafter picking up an organism morphologically resembling a phase-I organism, repeating the procedures of culturing and picking up, and converting the organisms to a heat-labile dermonecrotic toxin-producing ability negative phase-I organism having a complete capsular antigen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.